You are here
P&T January 2016
The agreement between Harvard Pilgrim and Amgen on a “pay for performance” deal involving evolocumab could encourage other manufacturers, health plans, and policy-makers to press for value-based pricing as drug costs continue to escalate.
Use of sodium polystyrene sulfonate (SPS) dominates the long-term treatment of hyperkalemia, but two new agents, sodium zirconium cyclosilicate and the recently FDA-approved patiromer, may offer potential advantages compared with SPS.
Coupled with administration support of an action plan that promotes quality of care and a culture of safety, the Medication Error Prioritization System (which automates parts of error review) has led to improvements for an integrated health care system.
Community liaison programs to cut hospital readmissions
FDA deluged with opinions on biosimilar naming plans.
FDA approvals, drug indications, and updates
Elotuzumab (Empliciti) and ixazomib (Ninlaro) for some multiple myeloma patients; Fluad (influenza vaccine, adjuvanted) for immunization of persons 65 years of age and older; and osimertinib (Tagrisso) for certain non–small-cell lung cancers
Alirocumab (Praluent): first in the new class of PCSK9 inhibitors
Key sessions at the meeting covered the effects and relationships of early remission, weight, corticosteroids, and anti-tumor necrosis factor agents in rheumatic diseases.
Analysts foresee substantial growth in the multiple myeloma market in the next decade, driven mainly by the monoclonal antibodies elotuzumab and daratumumab.